why is the fda banning compounded semaglutide moving to restrict mass-marketed GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified New Novo Nordisk initiatives support
Description
Singh, V
Three-minute assessment
And the published research adds credibility that most competitors lack
, Fruhbeck, G
